Loading...
INFI.Q logo

Infinity Pharmaceuticals, Inc.OTCPK:INFI.Q Rapport sur les actions

Capitalisation boursière US$90.0
Prix de l'action
US$0.000001
Ma juste valeur
Indisponible
1Y-100.0%
7D0%
1D
Valeur du portefeuille
Voir

Infinity Pharmaceuticals, Inc.

OTCPK:INFI.Q Rapport sur les actions

Capitalisation boursière : US$90.0

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Infinity Pharmaceuticals (INFI.Q) Aperçu de l'action

Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. Plus de détails

INFI.Q analyse fondamentale
Score flocon de neige
Évaluation2/6
Croissance future0/6
Performances passées0/6
Santé financière0/6
Dividendes0/6

INFI.Q Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Infinity Pharmaceuticals, Inc. Concurrents

Historique des prix et performances

Résumé des hausses, des baisses et des variations du cours de l'action pour la période du 1er janvier au 31 décembre 2009 Infinity Pharmaceuticals
Historique des cours de bourse
Prix actuel de l'actionUS$0.000001
Plus haut sur 52 semainesUS$0.26
Plus bas sur 52 semainesUS$0.000001
Bêta1.33
Variation sur 1 mois-99.00%
Variation sur 3 mois-99.96%
Variation sur 1 an-100.00%
Variation sur 3 ans-100.00%
Variation sur 5 ans-100.00%
Évolution depuis l'introduction en bourse-100.00%

Nouvelles et mises à jour récentes

Recent updates

Article d’analyse Nov 10

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha Sep 08

Infinity Pharmaceuticals: Waiting For A Deal

Summary Today, we revisit small oncology concern Infinity Pharmaceuticals for the first time in 2022. The company's primary drug Eganelisib has shown encouraging results as part of combination therapies, but the company is waiting on a collaboration deal to move development forward. Is a key strategic partnership worth the wait? An investment analysis follows in the paragraphs below. A man might share his wealth, but never his authority. - Amit Kalantri We concluded our last piece on Infinity Pharmaceuticals (INFI) in November 2021 saying it probably merited a small 'watch item' holding, preferably with a covered call position. Today, we follow up and see how this small biotech firm is progressing. An analysis follows below. Seeking Alpha Company Overview: Infinity Pharmaceuticals is headquartered in Cambridge, MA and its main focus continues to be developing novel medicines to treat cancer. This small oncology firm has a market cap of approximately $135 million and the stock trades near $1.50 a share. Pipeline: The company's core focus continues to be to develop its primary drug candidate Eganelisib as part of combination therapies to treat a variety of oncology indications. Eganelisib is a first-in-class, oral, once-daily, immuno-oncology (I/O) development candidate selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma). According to the company's website, Eganelisib works by: May Company Presentation Reprogramming key immune suppressive cells (called M2 macrophages or myeloid derived suppressor cells (MDSCs)) within the tumor microenvironment from a pro-tumor function to an anti-tumor function, decreasing immune suppression and increasing immune activation, ultimately leading to the activation and proliferation of T cells that can attack cancer cells. Company Website Since our last update around Infinity Pharmaceuticals, the company has disclosed some trial results. In December of last year, Infinity posted some updated data from its ongoing MARIO-3 study. This Phase 2 trial was designed to evaluate Eganelisib in combination with Roche's (RHHBY) atezolizumab (Tecentriq) and chemotherapy nab-paclitaxel (Abraxane) in frontline metastatic triple-negative breast cancer (TNBC). According to the lead scientist on the results showed 'Tumor reductions in 88.6% of evaluable patients were associated with a disease control rate of 81.4% in patients with PD-L1 negative tumors who are among the most challenging to treat'. The company should review updated PFS data from this study by the end of this year. Company Presentation Then a month ago, the company posted data from its two-year analysis of its phase 2 MARIO-275 study. This trial is evaluating Eganelisib in combination with Bristol-Myers' (BMY) Opdivo for the treatment of second line urothelial cancer. A key conclusion of the analysis was that 45% of patients in the Eganelisib combination treatment arm were alive compared to 24% of patients in just the Opdivo arm. In addition, this improvement was also seen in the PD-L1 negative tumor subgroup, with 38% of those patients alive at two years on the Eganelisib plus Opdivo arm versus only 17% on the Opdivo arm. These encouraging results are the key factor behind the recent rally in the stock. The only other active study is MARIO-1, which is in a far earlier stage of development, so is not germane to this analysis. Analyst Commentary & Balance Sheet: Over the past six months, five analyst firms including Piper Sandler and Oppenheimer have reissued Buy ratings on the stock. Albeit, three of these contain downward price target revisions. Price targets proffered range from $3 to $9 a share. JonesTrading maintained its Hold rating on INFI on August 12th.
Article d’analyse May 23

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Article d’analyse Dec 29

We're Hopeful That Infinity Pharmaceuticals (NASDAQ:INFI) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha Nov 25

Investigating Infinity Pharmaceuticals

Today we tee up a small 'off the radar' oncology concern called Infinity Pharmaceuticals for some in-depth research. The company posted encouraging trial results in July and is working with large drug makers to establish its primary candidate as part of combo therapies. A full investment analysis follows in the paragraphs below.
Article d’analyse Jul 18

Infinity Pharmaceuticals (NASDAQ:INFI) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Article d’analyse Jun 03

Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now

Performance at Infinity Pharmaceuticals, Inc. ( NASDAQ:INFI ) has been reasonably good and CEO Adelene Perkins has done...
Article d’analyse Apr 13

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Infinity...
Article d’analyse Feb 19

Are Institutions Heavily Invested In Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) Shares?

If you want to know who really controls Infinity Pharmaceuticals, Inc. ( NASDAQ:INFI ), then you'll have to look at the...
Article d’analyse Jan 15

Can You Imagine How Jubilant Infinity Pharmaceuticals' (NASDAQ:INFI) Shareholders Feel About Its 147% Share Price Gain?

Unfortunately, investing is risky - companies can and do go bankrupt. But if you pick the right stock, you can make a...
Article d’analyse Dec 11

Will Infinity Pharmaceuticals (NASDAQ:INFI) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Rendement pour les actionnaires

INFI.QUS BiotechsUS Marché
7D0%-1.6%-0.8%
1Y-100.0%34.4%27.1%

Rendement vs Industrie: INFI.Q a sous-performé le secteur US Biotechs qui a rapporté 34.4 % au cours de l'année écoulée.

Rendement vs marché: INFI.Q a sous-performé le marché US qui a rapporté 27.1 % au cours de l'année écoulée.

Volatilité des prix

Is INFI.Q's price volatile compared to industry and market?
INFI.Q volatility
INFI.Q Average Weekly Movement188.6%
Biotechs Industry Average Movement11.0%
Market Average Movement7.2%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.2%

Cours de l'action stable: Le cours de l'action de INFI.Q a été volatil au cours des 3 derniers mois par rapport au marché US.

Volatilité au fil du temps: La volatilité hebdomadaire de INFI.Q est passée de 89% à 189% au cours de l'année écoulée.

À propos de l'entreprise

FondéeSalariésPDGSite web
199530Seth Taskerwww.infi.com

Infinity Pharmaceuticals, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Infinity Pharmaceuticals se comparent-ils à sa capitalisation boursière ?
INFI.Q statistiques fondamentales
Capitalisation boursièreUS$90.00
Bénéfices(TTM)-US$40.95m
Recettes(TTM)US$2.57m
0.0x
Ratio P/S
0.0x
Ratio P/E

Le site INFI.Q est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
INFI.Q compte de résultat (TTM)
RecettesUS$2.57m
Coût des recettesUS$28.53m
Marge brute-US$25.96m
Autres dépensesUS$14.99m
Les revenus-US$40.95m

Derniers bénéfices déclarés

Jun 30, 2023

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)-0.45
Marge brute-1,010.35%
Marge bénéficiaire nette-1,593.93%
Ratio dettes/capitaux propres-127.9%

Quelles ont été les performances à long terme de INFI.Q?

Voir les performances historiques et les comparaisons

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2024/03/11 19:07
Cours de l'action en fin de journée2024/03/11 00:00
Les revenus2023/06/30
Revenus annuels2022/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Infinity Pharmaceuticals, Inc. est couverte par 23 analystes. de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Christopher RaymondBaird
Andrew D'SilvaB. Riley Securities, Inc.
Michael KingCitizens JMP Securities, LLC